Biodexa Pharmaceuticals PLC ADR (BDRX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
BDRX Chart
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the activation of the first clinical study site for its Serenta trial in patients with familial adenomatous polyposis (FAP). The trial, which is now enrolling, represents a significant milestone in the development of a potential new treatment option for FAP.
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce it has selected Serenta as the brand name for its upcoming phase 3 clinical study in familial adenomatous polyposis (FAP). In conjunction with this announcement, the company launched a dedicated website, www.serentatrial.com, to provide information and resources for patients, caregivers, and healthcare professionals.
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune system attacks and destroys the beta cells that produce insulin.
Biodexa Pharmaceuticals PLC ADR Dividends
Biodexa Pharmaceuticals PLC ADR Earnings
Biodexa Pharmaceuticals PLC ADR (BDRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biodexa Pharmaceuticals PLC ADR ever had a stock split?
Biodexa Pharmaceuticals PLC ADR Profile
| Biotechnology Industry | Healthcare Sector | Mr. Stephen Anthony Stamp CEO | NASDAQ (CM) Exchange | 59564R807 Cusip |
| GB Country | 13 Employees | - Last Dividend | 4 Oct 2024 Last Split | - IPO Date |
Overview
Biodexa Pharmaceuticals Plc is a clinical stage biopharmaceutical company dedicated to developing innovative solutions for Type 1 diabetes and rare/orphan brain cancers. Originating in 2000 and formerly known as Midatech Pharma plc until its rebranding in March 2023, the company is strategically based in Cardiff, the United Kingdom. Biodexa Pharmaceuticals Plc aims to advance the medical field with its cutting-edge research and developmental efforts, focusing on creating effective treatments that address the unmet needs in these challenging medical conditions.
Products and Services
-
Tolimidone
As Biodexa Pharmaceuticals Plc's lead product candidate, Tolimidone is a groundbreaking selective activator of the lyn kinase enzyme. It is currently under Phase II studies for its potential to treat Type 1 diabetes, exemplifying the company’s commitment to combating this chronic condition with innovative therapeutic methods.
-
MTX110
MTX110 represents a significant part of Biodexa Pharmaceuticals' pipeline, currently in Phase I studies targeting diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. This highlights the company's dedication to addressing some of the most challenging and rare cancer types with novel treatment options.
-
MTD217
This program revolves around MTD217, a water-soluble drug formulation designed for easy infusion or injection directly into the cancer microenvironment. Currently under preclinical studies for the treatment of leptomeningeal disease, MTD217 aims to offer a novel approach to challenging cancer treatments through targeted therapy.
-
Drug Delivery Platforms
Q-Sphera: A polymer microsphere microtechnology intended for sustained release drug delivery, showcasing Biodexa Pharmaceuticals' focus on innovative drug delivery solutions.
MidaSolve: An oligosaccharide nanotechnology designed to solubilize drugs for direct, local administration into tumors in liquid form, further exemplifying the company's innovative approach to cancer treatment.
MidaCore: Utilizes gold nanoparticles for disease site targeting, using chemotherapeutic or immunotherapeutic agents, highlighting the company’s investment in nanotechnology for precise and effective cancer therapy.
Contact Information
